Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-gal tumor lysate vaccine
- Development stage
- Preclinical
- Lead developer
- National Hospital Organization Kure Medical Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
The alpha-gal tumor lysate vaccine is an experimental immunotherapy designed to target cancer stem cells (CSCs) and differentiated tumor cells. The vaccine is produced by engineering tumor cells (such as the PANC1 pancreatic cancer line) to express alpha-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) through transfection with the alpha-1,3-galactosyltransferase (α1,3GT) gene. Because humans naturally possess high titers of anti-Gal antibodies, the presence of alpha-gal epitopes on the tumor lysate facilitates the formation of immune complexes. These complexes are efficiently opsonized and internalized by antigen-presenting cells, leading to the activation of tumor-specific T cells. Research indicates this approach can effectively target CSC markers like CD44 and CD24, potentially preventing tumor regrowth and metastasis.
- Other names
- α-gal tumor lysate vaccinealpha-gal epitope-expressing tumor lysate vaccine
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)alpha-gal (Alpha-gal epitope)Anti-Gal (Natural human anti-Gal antibody)
Beyond the preview
Go deeper on alpha-gal tumor lysate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-gal tumor lysate vaccine.